-
-
-
-
-
-
-
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-G
-
-
-
-
-
-
-
Candel Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
-
-
-
-
-
-
-
Candel Therapeutics Announces $25 Million Non-dilutive Debt Financing Agreement with Silicon Valley Bank
-
-
-
-
-
-
-
Candel Therapeutics to Participate in Three Upcoming Investor Conferences
-
-
-
-
-
-
-
Candel Therapeutics Appoints Mace L. Rothenberg, MD, as Senior Advisor to the Chief Executive Officer
-
-
-
-
-
-
-
Candel Therapeutics Announces Presentations of Key Clinical Data at AdMeTech and European Association of Neuro-Oncology Conferences in September 2021
-
-
-
-
-
66,415 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

